CTKB - Company ID 0001831915
The table below shows Cytek Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $53.23M | $48.14M | $44.13M | $52.29M | $45.60M | $41.46M |
| Cost of revenue | $22.02M | $19.80M | $22.88M | $24.74M | $21.73M | $21.30M |
| Gross profit | $31.21M | $28.34M | $21.25M | $27.55M | $23.87M | $20.16M |
| R&D | $9.36M | $9.74M | $9.60M | $8.96M | $8.83M | $9.72M |
Cytek Biosciences, Inc. reported annual revenue of $201.49M for fiscal year 2025. That is up 0.5% from $200.45M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $710.00K (FY 2020) to $201.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $18.36M | $16.82M | $18.47M | $16.12M | $13.53M | $12.90M |
| Operating income | -$8.42M | -$11.40M | -$18.46M | -$9.19M | -$10.62M | -$14.97M |
| Income tax | -$811.00K | $515.00K | $1.49M | -$2.29M | -$1.19M | $136.00K |
| Net income | -$6.10M | -$12.16M | -$18.87M | -$5.48M | -$5.58M | -$11.40M |
| EPS (diluted) | - | - | - | - | - | - |